Category Press Releases

Octave Bioscience Partners with Quest Diagnostics to Expand MSDA Test Access

Octave Bioscience Partners with Quest Diagnostics to Expand Nationwide Access to MSDA Test Octave Bioscience, a commercial-stage precision care company at the forefront of redefining disease management in multiple sclerosis (MS) and other neurodegenerative disorders such as Parkinson’s disease, today…

Read MoreOctave Bioscience Partners with Quest Diagnostics to Expand MSDA Test Access

Omeros Corporation Finalizes Asset Purchase and License Agreement with Novo Nordisk for MASP-3 Inhibitor Zaltenibart

Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed asset purchase and licensing transaction with Novo Nordisk, involving the…

Read MoreOmeros Corporation Finalizes Asset Purchase and License Agreement with Novo Nordisk for MASP-3 Inhibitor Zaltenibart
Cardiovascular

Corstasis and Cardiovascular Logistics Partner to Advance Outpatient Heart Failure Care

Corstasis Partners with Cardiovascular Logistics to Redefine Heart Failure Treatment Corstasis Therapeutics Inc., a commercial-stage biopharmaceutical company focused on advancing patient-centric, outpatient treatment strategies for cardiovascular and renal disorders, today announced a strategic collaboration with Cardiovascular Logistics (CVL). This collaboration…

Read MoreCorstasis and Cardiovascular Logistics Partner to Advance Outpatient Heart Failure Care
Guardant Health

ReAlta Life Sciences Announces Appointment of Dr. Howard Berman as Executive Chairman

ReAlta Life Sciences Strengthens Leadership Team with Appointment of Dr. Howard Berman as Executive Chairman ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company pioneering next-generation medicines designed to safely modulate neutrophils and the complement system, today…

Read MoreReAlta Life Sciences Announces Appointment of Dr. Howard Berman as Executive Chairman

Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor

Vyome Holdings Announces Appointment of Renowned Oncologist Dr. Aditya Bardia as Senior Medical Advisor to Advance VT-1953 for Malignant Fungating Wounds Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company focused on developing innovative dermatological and supportive-care therapies…

Read MoreVyome Appoints Dr. Aditya Bardia as Senior Medical Advisor

Microsize and Schedio Group Announce Acquisition of Lonza’s Micro-Macinazione Facility in Switzerland

Microsize and Schedio Group Sign Agreement to Acquire Lonza’s Micro-Macinazione Facility in Switzerland, Advancing a Transatlantic Particle Engineering Platform Microsize, a prominent contract development and manufacturing organization (CDMO) known for its leadership in particle size reduction, micronization, and advanced particle…

Read MoreMicrosize and Schedio Group Announce Acquisition of Lonza’s Micro-Macinazione Facility in Switzerland

U.S. FDA Grants Approval to PADCEV® and Keytruda® Combination for Select Bladder Cancer Patients

FDA Authorizes PADCEV® + Keytruda® Regimen for Eligible Individuals with Bladder Cancer Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV®…

Read MoreU.S. FDA Grants Approval to PADCEV® and Keytruda® Combination for Select Bladder Cancer Patients

Quanterix Announces Strategic Board and Leadership Transitions to Accelerate Future Growth

Quanterix Announces Comprehensive Board and Leadership Enhancements to Accelerate Its Next Phase of Strategic Growth Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in ultrasensitive biomarker detection and a pioneer in translating biomarker discoveries into impactful diagnostic…

Read MoreQuanterix Announces Strategic Board and Leadership Transitions to Accelerate Future Growth

ZIIHERA® + TEVIMBRA® Shows Strong Phase 3 Results in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines Announces Positive Phase 3 HERIZON-GEA-01 Results Supporting ZIIHERA®-Based Regimens as Transformative First-Line Options for HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to developing innovative therapies for hard-to-treat cancers,…

Read MoreZIIHERA® + TEVIMBRA® Shows Strong Phase 3 Results in First-Line HER2+ Gastroesophageal Cancer